Firms: One-Dose Anthrax Vaccine Effective in Animal Test

Anthrax spores, seen in an undated U.S. Defense Department pictomicrograph. Two companies reported indications that a single dose of their developmental anthrax vaccine could confer immunity to the deadly terrorism agent.
National Journal
Add to Briefcase
Diane Barnes
April 1, 2014, 11:04 a.m.

Two bi­o­tech­no­logy firms re­por­ted in­dic­a­tions that a single dose of their de­vel­op­ment­al an­thrax vac­cine could con­fer im­munity to the deadly ter­ror­ism agent.

Cur­rently, the only an­thrax vac­cin­a­tion au­thor­ized for use in the United States must be de­livered over sev­er­al months, in a course of five shots.

Pfenex in Cali­for­nia and Im­mun­o­vac­cine in Nova Sco­tia, though, said a single dose of their pro­pri­et­ary vac­cine promp­ted an im­mune re­sponse in rab­bits with­in 28 days.

The re­sponse “per­sisted un­til at least day 70 when an­im­als were ex­posed to the dis­ease agent,” the com­pan­ies said in a joint state­ment.

“All an­im­als vac­cin­ated with a single dose of mrPA - De­poVax con­tain­ing as little as one third of a mi­cro­gram of an­ti­gen were pro­tec­ted from an­thrax in­fec­tion,” the firms ad­ded.


Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.